1 Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002 [in eng]. Cancer causes & control : CCC 2008;19(4):379-390.
2 Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia [in eng]. The New England journal of medicine 2015;373(12):1136-1152.
3 Ding Y, Gao H, Zhang Q. The biomarkers of leukemia stem cells in acute myeloid leukemia [in eng]. Stem cell investigation 2017;4:19.
4 Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia [in eng]. Current opinion in hematology 2015;22(6):484-488.
5 Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells [in eng]. Cell 2009;138(2):286-299.
6 Jin L, Hope KJ, Zhai Q et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells [in eng]. Nature medicine 2006;12(10):1167-1174.
7 Hosen N, Park CY, Tatsumi N et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia [in eng]. Proceedings of the National Academy of Sciences of the United States of America 2007;104(26):11008-11013.
8 Mardiros A, Dos Santos C, McDonald T et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia [in eng]. Blood 2013;122(18):3138-3148.
9 Jin L, Lee EM, Ramshaw HS et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells [in eng]. Cell stem cell 2009;5(1):31-42.
10 Chung SS, Eng WS, Hu W et al. CD99 is a therapeutic target on disease stem cells in myeloid malignancies [in eng]. Science translational medicine 2017;9(374).
11 Kikushige Y, Shima T, Takayanagi S et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells [in eng]. Cell stem cell 2010;7(6):708-717.
12 Li C, Chen X, Yu X et al. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification [in eng]. International journal of clinical and experimental pathology 2014;7(10):6880-6888.
13 Herr MJ, Longhurst CM, Baker B et al. Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity [in eng]. Biochemical and biophysical research communications 2014;447(4):616-620.
14 Reyes R, Cardeñes B, Machado-Pineda Y et al. Tetraspanin CD9: A Key Regulator of Cell Adhesion in the Immune System [in eng]. Frontiers in immunology 2018;9:863.
15 Podergajs N, Motaln H, Rajčević U et al. Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells [in eng]. Oncotarget 2016;7(1):593-609.
16 Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes [in eng]. Nature reviews Immunology 2005;5(2):136-148.
17 Leung KT, Chan KY, Ng PC et al. The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells [in eng]. Blood 2011;117(6):1840-1850.
18 Hemler ME. Specific tetraspanin functions [in eng]. The Journal of cell biology 2001;155(7):1103-1107.
19 Hemler ME. Tetraspanin proteins promote multiple cancer stages [in eng]. Nature reviews Cancer 2014;14(1):49-60.
20 Wang VM, Ferreira RMM, Almagro J. CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth [in eng]. Nature Cell Biology 2019;21(11):1425-1435.
21 Touzet L, Dumezy F, Roumier C et al. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells [in eng]. Cancer Medicine 2019;8(3):1279-1288.
22 Nishida H, Yamazaki H, Yamada T et al. CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells [in eng]. Biochemical and biophysical research communications 2009;382(1):57-62.
23 Li H, Guo L, Jie S et al. Berberine inhibits SDF-1-induced AML cells and leukemic stem cells migration via regulation of SDF-1 level in bone marrow stromal cells [in eng]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2008;62(9):573-578.
24 Harrison JS, Wang X, Studzinski GP. The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts [in eng]. Oncotarget 2016;7(24):36447-36460.
25 Wobus M, Bornhäuser M, Jacobi A et al. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia [in eng]. Oncotarget 2015;6(36):38804-38815.
26 Shan J, Shen J, Wu M et al. Tcf7l1 Acts as a Suppressor for the Self-Renewal of Liver Cancer Stem Cells and Is Regulated by IGF/MEK/ERK Signaling Independent of β-Catenin. Stem Cells 2019;37(11):1389-1400.
27 Gentles AJ, Plevritis SK, Majeti R et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia [in eng]. Jama 2010;304(24):2706-2715.
28 Saito Y, Kitamura H, Hijikata A et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells [in eng]. Science translational medicine 2010;2(17):17ra19.
29 Ivey A, Hills RK, Simpson MA et al. Assessment of Minimal Residual Disease in Standard-Risk AML [in eng]. The New England journal of medicine 2016;374(5):422-433.
30 Krönke J, Schlenk RF, Jensen KO et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group [in eng]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(19):2709-2716.
31 Inaba H, Coustan-Smith E, Cao X et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia [in eng]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(29):3625-3632.
32 Buccisano F, Maurillo L, Del Principe MI et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia [in eng]. Blood 2012;119(2):332-341.
33 Terwijn M, van Putten WL, Kelder A et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study [in eng]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(31):3889-3897.
34 Walter RB, Buckley SA, Pagel JM et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission [in eng]. Blood 2013;122(10):1813-1821.
35 Othus M, Estey E, Gale RP. Assessment of Minimal Residual Disease in Standard-Risk AML [in eng]. The New England journal of medicine 2016;375(6):e9.
36 Taub JW, Berman JN, Hitzler JK et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial [in eng]. Blood 2017;129(25):3304-3313.
37 Hourigan CS, Gale RP, Gormley NJ et al. Measurable residual disease testing in acute myeloid leukaemia [in eng]. Leukemia 2017;31(7):1482-1490.
38 Buldini B, Rizzati F, Masetti R et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol [in eng]. British journal of haematology 2017;177(1):116-126.
39 Fuchs E, Horsley V. Ferreting out stem cells from their niches [in eng]. Nature cell biology 2011;13(5):513-518.
40 Medema JP, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer [in eng]. Nature 2011;474(7351):318-326.
41 Simons BD, Clevers H. Strategies for homeostatic stem cell self-renewal in adult tissues [in eng]. Cell 2011;145(6):851-862.
42 Cabrera MC, Hollingsworth RE, Hurt EM. Cancer stem cell plasticity and tumor hierarchy [in eng]. World journal of stem cells 2015;7(1):27-36.
43 Gupta PB, Pastushenko I, Skibinski A et al. Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance [in eng]. Cell stem cell 2019;24(1):65-78.
44 Gopal U, Gonzalez-Gronow M, Pizzo SV. Activated α2-Macroglobulin Regulates Transcriptional Activation of c-MYC Target Genes through Cell Surface GRP78 Protein [in eng]. The Journal of biological chemistry 2016;291(20):10904-10915.
45 Nagare RP, Sneha S, Krishnapriya S et al. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo [in eng]. Experimental cell research 2020;392(1):112009.
46 Ullah M, Akbar A, Thakor AS. An emerging role of CD9 in stemness and chemoresistance [in eng]. Oncotarget 2019;10(40):4000-4001.
47 Kersey JH, LeBien TW, Abramson CS et al. P-24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody [in eng]. The Journal of experimental medicine 1981;153(3):726-731.
48 Saygin C, Matei D, Majeti R et al. Targeting Cancer Stemness in the Clinic: From Hype to Hope [in eng]. Cell stem cell 2019;24(1):25-40.
49 Misra UK, Deedwania R, Pizzo SV. Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK [in eng]. The Journal of biological chemistry 2005;280(28):26278-26286.